MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.14
Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.56

10 Jan
2025

-0.060

OPEN

$4.62

-1.30%

HIGH

$4.70

124,478

LOW

$4.53

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved

EPS Basic

201920202021202220232024-400-300-200-1000
  • Negative
  • Growth
  • Slowing

DPS All

2019202020212022202320240204060
  • Negative
  • Growth
  • Slowing

Sales/Revenue

2019202020212022202320240200400600
  • Negative
  • Growth
  • Slowing

Book Value Per Share

201920202021202220232024050010001500
  • Negative
  • Growth
  • Slowing

Net Operating Cash Flow

201920202021202220232024-1000100200
  • Negative
  • Growth
  • Slowing

Net Profit Margin

201920202021202220232024-200-150-100-500
  • Negative
  • Growth
  • Slowing

Return on Capital Employed

201920202021202220232024-60-40-200
  • Negative
  • Growth
  • Slowing

Return on Invested Capital

201920202021202220232024-60-40-200
  • Negative
  • Growth
  • Slowing

Return on Assets

201920202021202220232024-30-20-100
  • Negative
  • Growth
  • Slowing

Return on Equity

201920202021202220232024-60-40-200
  • Negative
  • Growth
  • Slowing

Return on Total Capital

201920202021202220232024-30-20-10010
  • Negative
  • Growth
  • Slowing

Free Cash Flow ex dividends

201920202021202220232024-100-50050100
  • Negative
  • Growth
  • Slowing

Short-Term Debt

2019202020212022202320240100200300400500
  • Negative
  • Growth
  • Slowing

Long Term Debt

2019202020212022202320240100200300400
  • Negative
  • Growth
  • Slowing

Total Debt

2019202020212022202320240100200300400500
  • Negative
  • Growth
  • Slowing

Goodwill - Gross

2019202020212022202320240204060
  • Negative
  • Growth
  • Slowing

Cash & Equivalents - Generic

2019202020212022202320240100200300
  • Negative
  • Growth
  • Slowing

Price To Book Value

20192020202120222023202400.20.40.60.8
  • Negative
  • Growth
  • Slowing

Capex

2019202020212022202320240100200300
  • Negative
  • Growth
  • Slowing

Capex % of Sales

201920202021202220232024050100150
  • Negative
  • Growth
  • Slowing

Cost of Goods Sold

2019202020212022202320240100200300400
  • Negative
  • Growth
  • Slowing

Selling, General & Admin. Exp & Other

2019202020212022202320240100200300
  • Negative
  • Growth
  • Slowing

Research & Development

2019202020212022202320240102030
  • Negative
  • Growth
  • Slowing

Investments - Total

20192020202120222023202400.250.50.751
  • Negative
  • Growth
  • Slowing
  • Negative
  • Growth
  • Slowing
  • EXPERT VIEWS
    Display All Commentary

    Sentiment Indicator

    0.0

    No. Of Recommendations

    0
    EXTRA COVERAGE
    Display All Commentary

    No. Of Recommendations

    2

    Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

    MYX STOCK CHART